SABCS 2023 | Incorporating T-DXd in patients with HER2+ or HER2-low BC and leptomeningeal carcinomatosis

Marta Vaz Batista, MD, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal, gives her thoughts on the considerations that clinicians should take into account when incorporating trastuzumab deruxtecan (T-DXd) into the management of patients with HER2+ and HER2-low advanced breast cancer with leptomeningeal carcinomatosis, and the challenges which may arise in real-world clinical practice. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.